Sunitinib effectively interfere with the process of tumour angiogenesis by primarily diminishing signaling through VEGFR1, VEGFR2, which may indirectly reducing the level of VEGF, VEGFR1 and VEGFR231. The gene discussed is VEGFA; the disease is neoplasm.